Is Ketamine Legal for Therapy?

The Short Answer

Yes, ketamine is legal for medical use in the United States. It is an FDA-approved medication classified as a Schedule III controlled substance. Licensed healthcare providers can legally prescribe ketamine for approved indications and, under established medical practice, for off-label uses such as the treatment of depression, PTSD, and chronic pain.

FDA Approval Status

Approved Indications

Ketamine (racemic) was originally approved by the FDA in 1970 as a general anesthetic under the brand name Ketalar. It is approved for use as the sole anesthetic agent or as an induction agent prior to other anesthetics. This original approval remains in effect.

Esketamine (Spravato), the S-enantiomer of ketamine in nasal spray form, received FDA approval in:

• March 2019 — For treatment-resistant depression (TRD), in conjunction with an oral antidepressant
• August 2020 — For major depressive disorder (MDD) with acute suicidal ideation or behavior, in conjunction with an oral antidepressant

Off-Label Use

Racemic ketamine has not received specific FDA approval for psychiatric or pain indications (beyond anesthesia). However, off-label prescribing — the practice of prescribing an FDA-approved medication for a condition or in a manner not specified in its official labeling — is both legal and common in medicine.

Off-label prescribing accounts for a significant percentage of all prescriptions written in the United States. It is an accepted part of medical practice, supported by medical associations and recognized by the FDA itself. Physicians who prescribe ketamine off-label for depression, PTSD, anxiety, or chronic pain are practicing within established legal and professional boundaries.

Controlled Substance Classification

Schedule III Status

In 1999, the U.S. Drug Enforcement Administration (DEA) classified ketamine as a Schedule III controlled substance under the Controlled Substances Act. Schedule III substances are defined as drugs with:

• A moderate to low potential for physical and psychological dependence
• Currently accepted medical use in the United States
• A potential for abuse that is less than Schedule I and II substances

This classification means that ketamine can be legally manufactured, distributed, and prescribed, but is subject to specific regulatory controls:

• Prescriptions must be written by a DEA-registered practitioner
• Pharmacies must maintain accurate records of ketamine inventory
• There are limits on prescription refills
• Unauthorized possession or distribution is a criminal offense

Comparison to Other Substances

For context, Schedule III also includes medications such as testosterone, anabolic steroids, and products containing less than 90 milligrams of codeine per dosage unit. This classification reflects a moderate level of regulatory concern — less restrictive than Schedule II (which includes oxycodone, fentanyl, and methylphenidate) but more restrictive than Schedule IV (which includes benzodiazepines like diazepam and alprazolam).

State-Level Regulations

While federal law provides the overarching framework, individual states may impose additional regulations on ketamine prescribing and administration. Examples include:

• Some states have specific requirements for the clinical setting in which ketamine can be administered
• Certain states have enacted or proposed legislation related to telehealth prescribing of ketamine
• State medical boards may issue guidance on standards of care for ketamine therapy
• Some states require additional reporting or monitoring for controlled substance prescriptions through Prescription Drug Monitoring Programs (PDMPs)

Practitioners and patients should be aware of the specific regulations in their state.

Who Can Prescribe Ketamine?

In the United States, ketamine can be prescribed by:

• Physicians (MD/DO) — Including psychiatrists, anesthesiologists, emergency medicine physicians, pain management specialists, and primary care physicians
• Advanced practice providers — Nurse practitioners (NPs) and physician assistants (PAs) in many states, often with collaborative or supervisory agreements
• Dentists — For dental procedures (within the scope of their practice)

The prescriber must hold an active DEA registration and a valid state medical license. There is no special certification required to prescribe ketamine, though professional organizations have developed guidelines for training and competency. For advice on evaluating providers, see how to find a qualified ketamine provider.

International Legal Status

Ketamine's legal status varies by country:

• United Kingdom — Class B controlled drug; medical use is legal with appropriate prescribing
• Canada — Schedule I under the Controlled Drugs and Substances Act; medical use is legal
• Australia — Schedule 8 (controlled drug); medical use is legal with appropriate authorization
• European Union — Legal for medical use; regulatory classification varies by member state
• World Health Organization — Ketamine is on the WHO Model List of Essential Medicines; the WHO has actively opposed international scheduling that would restrict medical access

In many developing countries, ketamine is a critical anesthetic — sometimes the only available option — and efforts to restrict it at the international level have been met with significant opposition from the global health community.

The Evolving Regulatory Landscape

The regulatory landscape for ketamine therapy is evolving as its psychiatric applications become more widespread. Key developments include:

• DEA and telehealth — Following temporary relaxations during the COVID-19 pandemic, federal agencies have been reevaluating rules around prescribing controlled substances via telehealth. This has significant implications for at-home ketamine therapy programs.
• State legislation — Several states have introduced or passed legislation specifically addressing ketamine therapy, including requirements for clinical supervision and limits on at-home prescribing.
• Professional guidelines — Medical organizations including the American Psychiatric Association and the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) have issued guidelines aimed at standardizing clinical practice.

Key Takeaways

• Ketamine is a legal, FDA-approved medication classified as Schedule III
• Licensed practitioners can legally prescribe it for both on-label and off-label uses
• Esketamine (Spravato) has specific FDA approval for TRD and MDD with suicidal ideation
• Regulations vary by state, and the legal landscape is actively evolving
• Patients should ensure their provider is appropriately licensed and follows established clinical guidelines. For a complete introduction, see this guide to ketamine therapy

References

• MedlinePlus: Ketamine Injection — National Library of Medicine drug information on ketamine, including its FDA-approved status
• MedlinePlus: Esketamine Nasal Spray — National Library of Medicine information on esketamine (Spravato) and its FDA approval for psychiatric indications
• FDA: Drug Information — FDA resource on drug approvals, controlled substance regulations, and REMS programs
• StatPearls: Ketamine — Clinical reference covering ketamine's regulatory classification and prescribing framework